Methods for treatment of bladder cancer with gemcitabine
AssigneeTARIS Biomedical LLC
InventorsDennis Giesing, Heejin Lee, Karen Daniel
Life of this patent
Estimating the term…
Abstract
Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).
Claims5
A method for treating non-muscle invasive bladder cancer (NMIBC) in a human patient, comprising:
- administering from 10 mg/day to 50 mg/day of gemcitabine free base equipment (FBE) continuously to the bladder of the human patient over a treatment period of 21 days by deploying into the human patient's bladder an intravesical drug delivery device which comprises the gemcitabine and urea;
- wherein the intravesical drug delivery device comprises a housing that is elastically deformable between a retention shape configured to retain the intravesical drug delivery device in the bladder and a deployment shape for passage of the intravesical drug delivery device through a urethra,
- wherein the housing comprises a predefined release aperture and a drug reservoir, the drug reservoir having a first region and a second region that is a distinct space from the first region,
- wherein the gemcitabine is located in the first region in the form of one or more gemcitabine minitablets, and wherein the urea is located in the second region in the form of one or more urea minitablets;
- wherein the treatment does not comprise a therapeutic agent other than gemcitabine;
- releasing the gemcitabine from the predefined release aperture by osmotic pressure generated by the urea minitablets and into urine in the human patient's bladder,
- and
- wherein the human patient has not responded to Bacile Calmette-Guerin (BCG) treatment or wherein the human patient experienced adverse effects leading to discontinuation of BCG treatment.
Dependencies are inferred from the claim text.